Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-VEGFR-2 monoclonal antibody AK109

A human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, anti-VEGFR-2 monoclonal antibody AK109 specifically binds to and inhibits VEGFR-2 on vascular endothelial cells, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-VEGFR2 monoclonal antibody AK109
Code name:AK 109
AK-109
AK109
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search